INSMED INC Operating Lease, Payments
INSMED INC (INSM) reported Operating Lease, Payments of $11.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-19
- INSMED INC operating lease, payments for the quarter ending 2020-12-31 was $442.00K, a 93.61% decline year-over-year.
- INSMED INC operating lease, payments for the quarter ending 2020-09-30 was $1.46M.
- INSMED INC operating lease, payments for the quarter ending 2020-06-30 was $4.08M, a 58114.29% increase year-over-year.
- INSMED INC operating lease, payments for the quarter ending 2020-03-31 was $2.84M, a 9.44% decline year-over-year.
- INSMED INC operating lease, payments for fiscal 2025 was $11.04M, a 6.27% increase from fiscal 2024.
- INSMED INC operating lease, payments for fiscal 2024 was $10.39M, a 14.19% increase from fiscal 2023.
- INSMED INC operating lease, payments for fiscal 2023 was $9.10M, a 20.54% decline from fiscal 2022.
- INSMED INC operating lease, payments for fiscal 2022 was $11.45M, a 21.56% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.04M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $10.39M 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $9.10M 10-K · filed 2025-02-20 | |||
| 2022-12-31 | $11.45M 10-K · filed 2024-02-22 | |||
| 2021-12-31 | $14.60M 10-K · filed 2023-02-23 | |||
| 2020-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.90M derived: sum of 2 quarters · filed 2022-02-17 | $5.97M derived: sum of 3 quarters · filed 2022-02-17 | $8.81M 10-K · filed 2022-02-17 |
| 2020-09-30 | $1.46M 10-Q · filed 2020-10-29 | $5.53M derived: sum of 2 quarters · filed 2020-10-29 | $8.37M 10-Q · filed 2020-10-29 | $15.29M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | $4.08M 10-Q · filed 2020-08-06 | $6.91M 10-Q · filed 2020-08-06 | $13.83M derived: sum of 3 quarters · filed 2021-02-25 | $13.83M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | $2.84M 10-Q · filed 2020-04-30 | $9.76M derived: sum of 2 quarters · filed 2021-02-25 | $9.76M derived: sum of 3 quarters · filed 2021-02-25 | $9.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.92M derived: sum of 2 quarters · filed 2021-02-25 | $6.93M derived: sum of 3 quarters · filed 2021-02-25 | $10.06M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $6.00K derived: sum of 2 quarters · filed 2019-10-30 | $3.14M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.14M 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $3.13M 10-Q · filed 2019-05-07 | |||
| 2018-09-30 | $3.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $9.41M 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $6.28M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |